Alberto García-Ortega
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alberto García-Ortega has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Grace Oscullo
Respiratory Department, Hospital Universitario y Politécnico La Fe , Valencia
8 shared publications Grace Oscullo
Respiratory Department, La Fe University and Polytechnic Hospital, Valencia, Spain
7 shared publications- Miguel Ángel Martínez-García
Respiratory Department, Polytechnic and University Hospital la Fe, Valencia, Spain
5 shared publications Manuel Monreal
CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain; Chair for the Study of Thromboembolic Disease, Faculty of Health Sciences, UCAM - Universidad Católica San Antonio de Murcia, Spain
4 shared publicationsPilar Calvillo
Radiodiagnostic Department, Hospital La Fe, Valencia, Spain
4 shared publicationsAna Pedro-Tudela
Respiratory Department, Doctor Peset University Hospital, Valencia, Spain
3 shared publications
Latest Publications
- Open Access
- 23 April 2026
- Published by Fundacio Barcelona Respiratory Network in Barcelona Respiratory Network
- Vol. 8 (1)
Complexity and Heterogeneity in Bronchiectasis: Towards a Personalized Medicine
- 23 April 2026
- Published by Fundacio Barcelona Respiratory Network in Barcelona Respiratory Network
- Vol. 8 (1)
Open AccessComplexity and Heterogeneity in Bronchiectasis: Towards a Personalized Medicine
- Open Access
- 8 December 2025
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 49 (5)
An overlooked link: venous thromboembolism in obstructive sleep apnea
- 8 December 2025
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 49 (5)
Open AccessAn overlooked link: venous thromboembolism in obstructive sleep apnea
- Open Access
- 24 July 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Evaluation of microbial-derived metabolites in patients with acute pulmonary embolism: findings from the MICTEP study
Introduction: Functional analysis of microbiome with microbial-derived metabolites (MDMs) has emerged as key for several inflammatory and cardiovascular diseases. However, the data on the relationship of pulmonary embolism (PE) to microbiome are scarce. This study aimed to compare MDM levels between acute PE patients and healthy controls, and to investigate their associations with predisposing factors ( i.e. unprovoked, provoked and cancer-associated thrombosis). Methods: We collected serum samples from a multicentric cohort, including 96 patients with acute PE at hospital admission and 30 healthy controls. Serum concentrations of MDMs and inflammation/coagulation-related markers were quantified by liquid chromatography–mass spectrometry and flow cytometry, respectively. Results: Compared with healthy controls, patients with acute PE showed significantly higher serum levels of trimethylamine N-oxide (TMAO) (11.5 μM versus 6.7 μM; p=0.02) and acetate (48.3 μM versus 33.0 μM; p=0.04); and lower levels of propionate (3.8 μM versus 5.3 μM; p=0.007), butyrate (4.03 µM versus 7.68 µM; p=0.009), isobutyrate (5.0 μM versus 7.32 μM; p=0.002) and valerate (0.4 μM versus 0.63 μM; p<0.001). Valerate showed the best discrimination between PE and controls (area under the receiver operating characteristic curve 0.758, 95% CI 0.66–0.86). In the multinomial analysis, higher values of TMAO and acetate were associated with a higher probability of unprovoked PE. MDM levels exhibited different correlation with inflammation-related markers highlighting TGF-β1, CCL2 and CXCL10. Conclusion: These findings reveal imbalances in the serological concentrations of MDMs in patients with acute PE and highlight the potential role of the microbiome and its functional metabolites as novel predisposing risk factors for PE.
- 24 July 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Open AccessEvaluation of microbial-derived metabolites in patients with acute pulmonary embolism: findings from the MICTEP study
Introduction: Functional analysis of microbiome with microbial-derived metabolites (MDMs) has emerged as key for several inflammatory and cardiovascular diseases. However, the data on the relationship of pulmonary embolism (PE) to microbiome are scarce. This study aimed to compare MDM levels between acute PE patients and healthy controls, and to investigate their associations with predisposing factors ( i.e. unprovoked, provoked and cancer-associated thrombosis). Methods: We collected serum samples from a multicentric cohort, including 96 patients with acute PE at hospital admission and 30 healthy controls. Serum concentrations of MDMs and inflammation/coagulation-related markers were quantified by liquid chromatography–mass spectrometry and flow cytometry, respectively. Results: Compared with healthy controls, patients with acute PE showed significantly higher serum levels of trimethylamine N-oxide (TMAO) (11.5 μM versus 6.7 μM; p=0.02) and acetate (48.3 μM versus 33.0 μM; p=0.04); and lower levels of propionate (3.8 μM versus 5.3 μM; p=0.007), butyrate (4.03 µM versus 7.68 µM; p=0.009), isobutyrate (5.0 μM versus 7.32 μM; p=0.002) and valerate (0.4 μM versus 0.63 μM; p<0.001). Valerate showed the best discrimination between PE and controls (area under the receiver operating characteristic curve 0.758, 95% CI 0.66–0.86). In the multinomial analysis, higher values of TMAO and acetate were associated with a higher probability of unprovoked PE. MDM levels exhibited different correlation with inflammation-related markers highlighting TGF-β1, CCL2 and CXCL10. Conclusion: These findings reveal imbalances in the serological concentrations of MDMs in patients with acute PE and highlight the potential role of the microbiome and its functional metabolites as novel predisposing risk factors for PE.
- 28 June 2025
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 58 (7) , 882-892
Influence of patient’s weight and body mass index on presentation, time of onset, and impact of postoperative venous thromboembolism (RIETE registry)
- 28 June 2025
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 58 (7) , 882-892
Influence of patient’s weight and body mass index on presentation, time of onset, and impact of postoperative venous thromboembolism (RIETE registry)
- 22 January 2025
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
Pulmonary Embolism and Obstructive Sleep Apnea
Pulmonary embolism (PE) and obstructive sleep apnea (OSA) remain a major health issue worldwide with potential overlapping pathophysiological mechanisms. PE, the most severe form of venous thromboembolism, is associated with high morbidity and mortality, presenting challenges in management and prevention, especially in high-risk populations. OSA is a prevalent condition characterized by repeated episodes of upper airway closure resulting in intermittent hypoxia and sleep fragmentation. Although the understanding of epidemiological and pathogenic relationships between OSA and PE is still limited, current data suggest that interactions between these two conditions appear to be relevant. OSA is emerging as a novel risk factor for PE, potentially affecting all components of Virchow's triad: hypercoagulability, endothelial dysfunction, and venous stasis. Epidemiological studies indicate a high prevalence of undiagnosed OSA in acute PE patients. Moderate-to-severe OSA has been linked to worse clinical presentations and outcomes. Furthermore, OSA has been associated with increased risks of PE recurrence and mortality. Future research directions should include clarifying the bidirectional relationship between these conditions and evaluating the effectiveness and safety of continuous positive airway pressure therapy in improving outcomes in patients with concurrent acute PE and OSA.
- 22 January 2025
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
Pulmonary Embolism and Obstructive Sleep Apnea
Pulmonary embolism (PE) and obstructive sleep apnea (OSA) remain a major health issue worldwide with potential overlapping pathophysiological mechanisms. PE, the most severe form of venous thromboembolism, is associated with high morbidity and mortality, presenting challenges in management and prevention, especially in high-risk populations. OSA is a prevalent condition characterized by repeated episodes of upper airway closure resulting in intermittent hypoxia and sleep fragmentation. Although the understanding of epidemiological and pathogenic relationships between OSA and PE is still limited, current data suggest that interactions between these two conditions appear to be relevant. OSA is emerging as a novel risk factor for PE, potentially affecting all components of Virchow's triad: hypercoagulability, endothelial dysfunction, and venous stasis. Epidemiological studies indicate a high prevalence of undiagnosed OSA in acute PE patients. Moderate-to-severe OSA has been linked to worse clinical presentations and outcomes. Furthermore, OSA has been associated with increased risks of PE recurrence and mortality. Future research directions should include clarifying the bidirectional relationship between these conditions and evaluating the effectiveness and safety of continuous positive airway pressure therapy in improving outcomes in patients with concurrent acute PE and OSA.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA751
Role of microbial-derived metabolites in the pulmonary embolism. MICTEP study.
Introduction: Functional analysis of microbiome with microbial-derived metabolites (MDM) has emerged with potential implications for cardiovascular diseases, but knowledge about its role in pulmonary embolism (PE) is still limited. Aims: To compare the levels of MDM in PE patients with a control group, as well as its association with risk factors (RF) for PE. Material and methods: Observational study of patients with acute PE prospectively enrolled in the RIETE registry and a prospective cohort of healthy subjects with no previous history of PE was included for control group. PE was defined as provoked in the presence of any of the following RF: recent immobilization, surgery, estrogen use, pregnancy, postpartum period, or long-haul travel. Cancer associated PE was considered when concomitant cancer. Alternatively, PE was considered unprovoked in the absence of all these RF. Results: 96 patients with acute PE were included (49% women, 63±16 yrs, 81±16 kg), along with 30 healthy controls (50% women, 49±5 yrs, 77±9 kg). 67 patients had unprovoked PE. Compared to control group, PE patients had higher levels of trimethylamine N-oxide (11.5 µM vs 6.7 µM;p=0.02) and acetate (48.3 µM vs 33.0 µM;p=0.04), and lower levels of propionate (3.8 µM vs 5.3 µM;p=0.007), isobutyrate (5.0 µM vs 7.32 µM;p=0.002), and valerate (0.4 µM vs 0.63 µM;p<0.001). Compared to provoked PE patients, unprovoked PE patients had higher levels of acetate (p=0.04). Acetate showed the ability to differentiate unprovoked PE and provoked PE by different factors from cancer (AUC 0.67;95%CI 0.52-0.86). Conclusions: PE patients exhibit a different metabolomic profile compared to controls, with relevant differences based on their triggering RF.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA751
Role of microbial-derived metabolites in the pulmonary embolism. MICTEP study.
Introduction: Functional analysis of microbiome with microbial-derived metabolites (MDM) has emerged with potential implications for cardiovascular diseases, but knowledge about its role in pulmonary embolism (PE) is still limited. Aims: To compare the levels of MDM in PE patients with a control group, as well as its association with risk factors (RF) for PE. Material and methods: Observational study of patients with acute PE prospectively enrolled in the RIETE registry and a prospective cohort of healthy subjects with no previous history of PE was included for control group. PE was defined as provoked in the presence of any of the following RF: recent immobilization, surgery, estrogen use, pregnancy, postpartum period, or long-haul travel. Cancer associated PE was considered when concomitant cancer. Alternatively, PE was considered unprovoked in the absence of all these RF. Results: 96 patients with acute PE were included (49% women, 63±16 yrs, 81±16 kg), along with 30 healthy controls (50% women, 49±5 yrs, 77±9 kg). 67 patients had unprovoked PE. Compared to control group, PE patients had higher levels of trimethylamine N-oxide (11.5 µM vs 6.7 µM;p=0.02) and acetate (48.3 µM vs 33.0 µM;p=0.04), and lower levels of propionate (3.8 µM vs 5.3 µM;p=0.007), isobutyrate (5.0 µM vs 7.32 µM;p=0.002), and valerate (0.4 µM vs 0.63 µM;p<0.001). Compared to provoked PE patients, unprovoked PE patients had higher levels of acetate (p=0.04). Acetate showed the ability to differentiate unprovoked PE and provoked PE by different factors from cancer (AUC 0.67;95%CI 0.52-0.86). Conclusions: PE patients exhibit a different metabolomic profile compared to controls, with relevant differences based on their triggering RF.
- Open Access
- 5 June 2024
- Published by Elsevier in Open Respiratory Archives
- Vol. 6 (4) , 100342
Tromboembolia de pulmón
- 5 June 2024
- Published by Elsevier in Open Respiratory Archives
- Vol. 6 (4) , 100342
Open AccessTromboembolia de pulmón
- 4 January 2024
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 60 (3) , 143-152
Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry
- 4 January 2024
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 60 (3) , 143-152
Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry
- Open Access
- 11 November 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7, 100358
OC 05.1 Impact of Low Molecular Weight Heparin (LMWH) on SARS-CoV2 Infection: HEPARIN-SARS-CoV2 Clinical Trial
- 11 November 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7, 100358
Open AccessOC 05.1 Impact of Low Molecular Weight Heparin (LMWH) on SARS-CoV2 Infection: HEPARIN-SARS-CoV2 Clinical Trial
- 10 October 2023
- Published by Elsevier in Sleep Medicine
- Vol. 112, 88-95
Changes in sleep-disordered breathing from the acute to the stable phase of pulmonary embolism: The ESAET study
- 10 October 2023
- Published by Elsevier in Sleep Medicine
- Vol. 112, 88-95
Changes in sleep-disordered breathing from the acute to the stable phase of pulmonary embolism: The ESAET study